- This topic is empty.
-
Posts
-
VivaDiag Molecular System: Professional IVD Use, Explained
Introduction: Defining Professional IVD Use
Professional in vitro diagnostic (IVD) use describes diagnostic testing performed by clinical laboratory professionals using regulated devices and reagents — as distinct from self-testing or near-patient testing. The distinction matters commercially and clinically: it determines which regulatory pathway applies, which operator training is assumed, and where a device is permitted to sit in the care pathway.
VivaChek Biotech (Hangzhou) Co., Ltd., headquartered in Linping District, Hangzhou, Zhejiang, China, is a medical device manufacturer that has organized its portfolio around that definition. Under the VivaDiag diagnostic product brand and the VivaChek corporate brand, the company supplies a portable fluorescence immunoassay (FIA) analyzer ecosystem paired with disposable quantitative test kits, certified for professional use in European markets. This article examines what that system covers, how it is specified, and where it fits in real clinical workflows.
The Problem the VivaDiag Platform Addresses
Traditional fluorescence immunoassay testing has been constrained by laboratory-bound instruments, large sample volume requirements, long turnaround times, and high operational costs. Those constraints limit access to timely diagnostics at the point of care — precisely where a quantitative result changes a clinical decision.
Prostate health illustrates the pressure. Prostate cancer is the second most common cancer in men globally, with about 1.47 million new cases and about 400,000 deaths worldwide in 2022. Early prostate cancer often presents with few or no symptoms, so accessible screening and assessment tools carry disproportionate weight. Aging populations increase the disease burden further. Central laboratory testing involves venipuncture, larger sample volumes, and longer turnaround, which creates barriers to timely point-of-care assessment.
A Portable FIA Ecosystem for Professional IVD Use
The VivaDiag analyzer line is built on a fluorescence immunochromatography technology platform, with a photoelectric detection based immunofluorescence detection device and an ID Card coding system for test parameter calibration. Three analyzer models sit in the current portfolio.
VivaDiag Portable FIA Analyzer VIM300H is the model introduced in 2026. It measures 146 x 77.6 x 55.5 mm, weighs 370 g, and carries a 3.97-inch color touch screen. A removable and rechargeable lithium battery supports up to 10 hours of continuous operation, with backup power support. Memory holds 10,000 results. Connectivity includes USB, Wi-Fi, and Bluetooth (optional), with an external Bluetooth printer available as an option. Operating temperature is 5–40°C and storage temperature is -10–55°C. Sample types supported span whole blood, serum, plasma, urine, hair, and other sample types. The test menu covers 39 venous-blood parameters and more than 20 capillary-blood-ready parameters.
VIM3000 is a prior-generation model weighing 1.8 kg with a 7-inch color touch screen and a built-in thermal printer, sized 192 x 209 x 169 mm, with Ethernet port RJ-45, USB, and Wi-Fi connectivity and 10,000-result memory. VIM220H is the compact prior-generation option at 165 g, measuring 124.5 x 72.5 x 40 mm, with a 1.54-inch LCD display, 999-result memory, and optional Bluetooth printing.
The VivaDiag PSA Test Kit (FIA): Quantitative Results in 15 Minutes
The VivaDiag Prostate Specific Antigen (PSA) Test Kit (FIA), catalog number VID24-06-011, is a fluorescence immunoassay for the quantitative determination of PSA in human whole blood obtained by fingerstick or venipuncture, serum, or plasma, delivering results in 15 minutes.
Its stated measuring range is 0.1–100 ng/mL for serum and plasma and 0.37–100 ng/mL for whole blood, with a cut-off reference range of 4 ng/mL. Sample volume is 20 µL, which enables fingerstick whole blood testing with minimal patient burden. Intermediate precision is reported at CV = 4.97% at low concentration, 4.05% at medium concentration, and 4.69% at high concentration. Operation temperature is 18–25°C.
Each kit contains 25 test devices, 25 buffer tubes, 25 safety lancets, 25 alcohol prep pads, 25 x 20 µL pipettes, 25 x 75 µL pipettes, and 1 ID Card. The ID Card supports analyzer calibration for the specific parameter.
Data Handling and Workflow Integration
For professional users, record retention and transferability matter as much as analytical performance. The VIM300H stores 10,000 results and offers USB, Wi-Fi, and Bluetooth (optional) connectivity, while the VIM3000 adds an Ethernet port RJ-45 for wired laboratory information system integration. Unit conversion is supported on both the VIM300H and VIM3000. The system is designed for hardware analyzer and disposable test kit pairing, with ID Card coding aligning each kit to its parameter calibration.
Regulatory Foundation
VivaChek Biotech holds an EU Quality Management System Certificate under Regulation (EU) 2017/746 on In Vitro Diagnostic Devices, Annex IX Chapter I and III, with CE Marking under Notified Body Identification Number 0344 — DEKRA. The PSA Test Kit is described as IVDR-certified for professional use. This regulatory position underpins market access in European priority markets: Germany, France, Italy, Spain, and the UK, alongside broader global coverage.
Where the System Fits in Practice
Intended for use by clinical laboratory professionals, the platform addresses settings where quantitative testing previously required central laboratory processing.
Primary healthcare — GP clinics and surgeries, community health centers, township and rural clinics, and walk-in care facilities.
Emergency and pre-hospital care — ambulances and paramedic units, mobile medical units, emergency department triage, and urgent care centers.
Niche and decentralized settings — corporate and school health clinics, retail pharmacy testing services, home healthcare and domiciliary visits, research and field operations, and remote offshore and maritime stations.
Across these settings, three design choices carry operational weight: a 10-hour battery runtime that supports continuous operation across clinical shifts and mobile workflows; a 370 g handheld form factor suitable for ambulance, field, and bedside use; and touchscreen operation that streamlines the testing workflow and reduces training burden.
Deployment and Launch Readiness
Delivery follows a professional-use model: a hardware analyzer system paired with disposable FIA test kits, with 25 test devices per PSA kit. The PSA Test Kit and the VIM300H were introduced in 2026. Launch preparation has proceeded in stages — 32 sample units were readied for distribution before Mid-Autumn Festival, approximately 78 finished units were made available for distribution by late October, and trial production is scheduled to conclude in December. Buyers evaluating the platform for 2026–2027 planning should confirm current unit availability directly with the manufacturer.
Questions Buyers Commonly Ask
Is the system intended for self-testing? No. It is for in vitro diagnostic use only, intended for clinical laboratory professionals, and not intended for self-testing or near-patient testing.
What sample types are accepted? Whole blood, serum, plasma, urine, hair, and other sample types, depending on the test kit and analyzer model.
How is calibration handled? Through ID Card coding, which carries parameter-specific calibration for the analyzer.
Which markets are prioritized? Germany, France, Italy, Spain, and the UK, within a broader global footprint.
Conclusion
For laboratories and healthcare organizations evaluating portable quantitative immunoassay capability, the relevant questions are regulatory status, analytical specification, and workflow fit. VivaChek Biotech (Hangzhou) Co., Ltd. answers each with documented detail: IVDR certification under Notified Body 0344, a PSA assay measuring 0.1–100 ng/mL on serum and plasma with a 20 µL sample volume and a 15-minute result, and a 370 g analyzer with a 10-hour battery and a test menu spanning 39 venous-blood parameters and more than 20 capillary-blood-ready parameters. The company’s positioning is straightforward — delivering laboratory-quality quantitative immunoassay results outside the central laboratory, and expanding access to prostate health assessment and other diagnostic testing across primary care, emergency, and field settings.
- You must be logged in to reply to this topic.